Table 3.
Observed baseline characteristics of patients treated with BAY 94-9027 and rAHF-PFM
| Baseline characteristicsb | Before matching | After matchinga | ||||
|---|---|---|---|---|---|---|
| BAY 94-9027 | rAHF-PFM (2004 study)a |
P | BAY94-9027 | rAHF-PFM (2004 study)a |
P | |
| N=104 | N=107 | N=104 | N=107 | |||
| Age ≤18 years | 13 (12.5%) | 54 (50.0%) | <0.001* | 50.0% | 50.0% | 1.00 |
| Ethnicity | ||||||
| White | 73 (70.2%) | 99 (92.8%) | <0.001* | 92.8% | 92.8% | 1.00 |
| Asian | 27 (26.0%) | 1 (0.9%) | <0.001* | 0.9% | 0.9% | 1.00 |
| Prior treatment typea | ||||||
| Prophylactic | 84 (80.8%) | 78 (73.0%) | 0.23 | 73.0% | 73.0% | 1.00 |
| On-demand | 20 (19.2%) | 29 (27.0%) | 0.23 | 27.0% | 27.0% | 1.00 |
| Baseline characteristicsb | BAY 94-9027 | rAHF-PFM (2012 study) | P | BAY 94-9027 | rAHF-PFM (2012 study) | P |
| N=104 | N=66 | N=104 | N=66 | |||
| Age <16 years | 9 (8.7%) | 9 (13.6%) | 0.44 | 13.6% | 13.6% | 1.00 |
| Ethnicity | ||||||
| White | 73 (70.2%) | 58 (87.9%) | <0.05* | 87.9% | 87.9% | 1.00 |
| Asian | 27 (26.0%) | 1 (1.5%) | <0.001* | 1.5% | 1.5% | 1.00 |
| Presence of target joint(s) | 78 (75.0%) | 63 (95.5%) | <0.001* | 95.5% | 95.5% | 1.00 |
Notes: aThe effective sample size of the BAY 94-9027 overall group was 25.32 after matching with the 2004 study and 55.33 after matching with the 2012 study. bPatients on both prior prophylactic and on-demand treatment in the 2004 study were categorized as being on “prior prophylactic treatment” to be consistent with the definition in the PROTECT VIII trial. *P<0.05.
Abbreviation: rAHF-PFM, recombinant antihemophilic factor–plasma/albumin-free method.